A PHARMACEUTICAL COMPANY WITH A PASSION FOR RESEARCH & INNOVATION
Our vision is to sustainably improve the life prospects of people with serious diseases. To achieve this, Bioprojet works together with researchers, doctors and other healthcare professionals worldwide.
A fundamental discovery related to a histamine receptor (H3) resulted in the development of pitolisant. The drug, which is commercialized under the name Wakix®, is indicated in adults for the treatment of narcolepsy, with or without cataplexia. Wakix® has been registered in the 28 countries of the European Union since 2016, and recently the FDA has also registered Wakix®.